Physician profile
Robin L Vargo
NPI 1629378641
$903.23
in general payments reported to CMS, 2019-2025
14 companies · $65.11 in 2025
The $65.11 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $356 · 2024: $482 · 2025: $65.11.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $624 · Education: $279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $624.29 |
| Education | $278.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $204.96 | 2023-2025 | Keytruda, Lynparza, Reblozyl |
| Sanofi-Aventis U.S. LLC | $194.95 | 2023 | |
| Abbvie INC. | $119.92 | 2024-2025 | |
| Agios Pharmaceuticals, INC. | $116.67 | 2024 | Pyrukynd |
| Pfizer INC. | $45.68 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $38.73 | 2023-2024 | Calquence, Tagrisso |
| E.R. Squibb & Sons, L.L.C. | $36.56 | 2023-2024 | Opdualag, Opdivo |
| Eisai INC. | $25.15 | 2024 | |
| Daiichi Sankyo INC. | $24.80 | 2024 | Vanflyta |
| Novartis Pharmaceuticals Corporation | $24.64 | 2024 | |
| Astellas Pharma US INC | $20.38 | 2023 | Padcev |
| Deciphera Pharmaceuticals INC. | $18.12 | 2023 | Qinlock |
| Celgene Corporation | $16.71 | 2023 | Reblozyl |
| Pharmacyclics LLC, An Abbvie Company | $15.96 | 2023 | Imbruvica |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Vargo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.